During ESMO Congress 2023, sessions will focus on hot topics in therapeutic areas, such as the use of immunotherapies in both the neoadjuvant and adjuvant settings, as well as nontherapeutic topics, such as the needs of caregivers and advances in technology.
The latest data on drug regimens in a variety of cancers will take the stage at ESMO Congress 2023. In addition, the conference schedule is focusing on new technologies and access to treatments. This year, ESMO Congress 2023 will be held both virtually and in person in Madrid, Spain.
The Congress will offer 105 late-breaking abstracts, which will be presented during the 3 Presidential sessions, as well as additional Proffered Paper sessions.
Among the trials being presented are results on the use of immunotherapy in both the neoadjuvant and adjuvant settings to treat various cancers. There will also be a session delving into the use of adjuvant or neoadjuvant immunotherapy or both in localized non–small cell lung cancer (NSCLC), with speakers from Hong Kong, Spain, Poland, and Italy. There will be interim results of the CheckMate-77T phase 3 study of neoadjuvant nivolumab plus chemotherapy followed by surgery and adjuvant nivolumab.
The same session, Presidential 1 held 4:30 pm CEST on Saturday, will include results from LIBRETTO-431, a randomized, open-label phase 3 trial of first-line selparcatinib with or without pembrolizumab vs chemotherapy with or without pembrolizumab. Results from the phase 3 randomized global study PAPILLON evaluating amivantamab plus chemotherapy vs chemotherapy alone also will be presented.
In addition, the meeting will present findings from trials on antibody drug conjugates (ADCs) in a range of cancers:
Outside of the therapeutic presentations, there will be sessions on access to and affordability of cancer drugs, early detection and prevention, and supportive and palliative care. In addition, there will be multiple presentations on new technologies, including a session on Saturday on big data and artificial intelligence (AI). On Monday there is a session on the use of AI in prognostication.
There is also a focus on caregivers. The first day of the meeting will include a session with speakers from Belgium, Sweden, the United Kingdom, Romania, and Portugal discussing the needs of caregivers both during the patient journey and after end of life. Sunday furthers the discussion with a session on caring for the caregivers.
The entire meeting will round out with 2 Scientific Congress Highlights sessions, reviewing the discussions in topics such as breast cancer, policy and preventive strategies, investigational immunotherapies, head and neck cancer, hematological malignancies, and NSCLC.
CMS' 340B Repayment Proposal May Harm Vulnerable Hospitals, Reward Those With Higher Revenues
April 26th 2024The 340B hospitals not receiving an offsetting lump-sum payment from CMS following 2018-2022 cuts later ruled unlawful are disproportionately rural, publicly owned, and nonacademic, according to a new study.
Read More
Navigating Health Policy in an Election Year: Insights From Dr Dennis Scanlon
April 2nd 2024On this episode of Managed Care Cast, we're talking with Dennis Scanlon, PhD, the editor in chief of The American Journal of Accountable Care®, about prior authorization, price transparency, the impact of health policy on the upcoming election, and more.
Listen
Kaiser Permanente was hit by a data breach in mid-April, impacting 13.4 million health plan members; GlaxoSmithKline (GSK) sued Pfizer and BioNTech for allegedly infringing on its messenger RNA technology patents in the companies’ COVID-19 vaccines; the CDC announced the first-known HIV cases transmitted via cosmetic injections.
Read More